Introduction
Datamonitor analyses the cardiovascular and metabolic biologic markets, current regulatory standing and the market potential for biosimilars. Fractionated heparin Lovenox and the leading human insulin analogs: Lantus, NovoRapid, Humalog are highlighted as the most attractive targets for biosimilar versions and subjected to scenario based forecasting to 2019
Features and benefits
- quantify seven major market sales of biologic drugs used in cardiovascular and metabolic disease
- understand the historical and forecast growth of key biologic drug classes
- assess the future performance of leading biologic agents
- analyze likely biosimilar erosion of leading biologic agents with scenario based forecasts
Highlights
The majority of future biosimilar sales will be in the heparin and insulin classes – In the cardiovascular and metabolic space 95% of all biologic drug sales are forecast to come from the insulin and heparin classes. Datamonitor forecast the most attractive brands within these classes to support large biosimilar markets by 2019
Lovenox already has generic competition in the US from July 2010 after the approval of M-enoxaparin through an abbreviated new drug application. Lantus, NovoRapid, and Humalog brands are collectively forecast to generate $7.2 billion in 2010 but are all forecast to grow further providing attractive targets for biosimilar versions
Scenario based forecasts show that whilst greater biosimilar erosion redistributes revenues away from originator company, reductions in the overall market value are comparatively small. Datamonitor forecast biosimilar versions of leading cardiovascular biologic brands to establish a substantially sized market by 2019
Your key questions answered
- Biosimilars are a new challenge for the branded industry, identify the key areas which they will impact the cardiovascular market
- The forecast growth of biosimilars to 2019 will likely be confined to certain cardiovascular drug classes and regional markets; understand why
- Lovenox generics entered the US market in July 2010, analyze the brand erosion by off-patent enoxaparin using scenario based forecasts